medigraphic.com
ISSN 0035-0052 (Impreso)

2002, Número 4

<< Anterior Siguiente >>

Rev Mex Pediatr 2002; 69 (4)


Eficacia terapéutica con topiramato y valproato de magnesio en niños con síndrome de Lennox-Gastaut

Gutiérrez MJ, Villegas PH, Espinosa ZJP

Idioma: Español
Referencias bibliográficas: 25
Paginas: 139-143
Archivo PDF: 192.03 Kb.


RESUMEN

Objetivo. Conocer la eficacia del topiramato y valproato de magnesio en niños con el síndrome de Lennox-Gastaut (SLG).
Sujetos. Se estudiaron 11 niños con SLG, cuatro mujeres y siete hombres, todos tratados durante seis meses con estos medicamentos. Se registró el tipo de crisis convulsivas y los efectos adversos al tratamiento. En cada niño se llevó control elecroencefalográfico y de exámenes de laboratorio.
Resultados. La respuesta al tratamiento fue excelente en las tónico clónicas generalizadas y en las ausencias atípicas. En las crisis mioclónicas se obtuvo menor respuesta al tratamiento. Como efectos adversos se registraron en cinco niños (pérdida de peso, somnolencia, ataxia y trombocitopenia).
Conclusiones. El topiramato en combinación con valproato de magnesio es efectivo en el tratamiento de niños con el SLG de difícil control.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Baziel GM et al. Serologic HLA typing in cryptogenic Lennox-Gastaut syndrome. Epilepsy Research 1997; 17: 43-47.

  2. Eriksson KJ, Koivikko MJ. Prevalence, classification and severity of epilepsy and epileptic syndromes in children. Epilepsy 1997; 38: 1275-82.

  3. Commission on classification and terminology of the international league against epilepsy. Proposal for revised. Classification of epilepsies and epileptic syndromes: Epilepsy 1989; 30: 389-399.

  4. Doose DR. Pharmacokinetic properties of topiramate. Round Table Series 1996; 39: 11-6.

  5. Chadwick D, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: An overview of safety and efficacy. Epilepsy 1996; 37(Suppl. 6): S17-S22.

  6. Marson AG, Kadir Z, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. British Medical Journal 1996; 313: 1169-74.

  7. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW. Topiramate placebo controlled dose-raging trial in refractory partial epilepsy using 200, 400 and 600 mg daily dosages. Neurology 1996; 46: 1685-1690.

  8. Menachem E. Drug evaluation central & peripheral nervous systems. Topiramate: Current status and therapeutic potential. Exp Opin Invest Drugs 1997; 6: 1085-94.

  9. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research 1996; 25: 217-224.

  10. Rosenfeld WE, Liao S, Krammer LD, Anderson G, Palmer M, Levy R. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patient with epilepsy during monotherapy and concomitant therapy. Epilepsy 1997; 38: 324-333.

  11. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsy 1996; 137(8): 774-780.

  12. International symposium proceedings. Topiramate: A promising new agent for the treatment of epilepsy. Advances in AED therapy 1995; 1: 1-29.

  13. Biton V, Montouris GD, Ritter F, Riviello J, Lim P, Pledger G. The topiramate YTC study group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 1330-37.

  14. Glauser T. Preliminary observations on topiramate in pediatric epilepsies. Epilepsy 1997; 38(Suppl. 1): S37-S41.

  15. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: Review and comparison with other new antiepileptic drugs. Epilepsy 1997; 8(Suppl. 1): S18-S23.

  16. Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsy 1997; 8(Suppl. 1): S24-S27.

  17. Elterman RD, Glauser TA, Wyllie E, Wu SC. The topiramate YP study group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52: 1338-44.

  18. Dreifuss F. Epilepsies with partial seizures in childhood. J Child Neurol 1997; 12(Suppl. 1): S19-S22.

  19. Biton V. Preliminary open-label experience with topiramate in primary generalized seizures. Epilepsy 1997; 38(Suppl. 1): S42-S44.

  20. Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: The european experience. Epilepsy 1997; 38(Suppl. 1): S28-S30.

  21. Rosenfeld WE, Sachdeo RC, Faught RE. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: Retrospective survey of open-label treatment. Epilepsy 1997; 38(Suppl. 1): S34-S36.

  22. Wilner A, Raymond K, Pollar R. Topiramate and metabolic acidosis. Epilepsy 1999; 40: 792-795.

  23. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsy 1997; 38(Suppl. 1): S59-S62.

  24. Sachdeo R, Reife R, Lim P, Fledger G. Topiramate monotherapy for partial onset seizures. Epilepsy 1997; 38: 294-300.

  25. Sachdeo RC, Glauser TA, Ritter F, Riefe R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52: 1882-87.




2020     |     www.medigraphic.com